Retatrutide 'Week 3' TikTok updates: hype vs. trial data

What did @chelseypeptides actually say?

This is a personal week-3 progress update on retatrutide, a triple-hormone receptor agonist currently in clinical trials. The creator reports that appetite suppression is still strong, early headaches have resolved, she feels unusually confident, and she had mild nausea after eating sugary food. No doses, protocols, or sourcing details were mentioned, which is worth noting.

Her framing is experiential rather than medical, and she owns that energy. She is not claiming retatrutide cures anything. She is describing what she is feeling, week by week. That is a different category of content than medical advice, though it still shapes how viewers think about this compound.

Does the science back this up?

Mostly, yes. The side effect profile she describes is consistent with what Phase 2 trial data has shown for retatrutide. This is not a coincidence or confirmation bias. These are the same adverse events researchers documented in controlled settings.

Retatrutide is a GIP, GLP-1, and glucagon receptor triagonist. In the Phase 2 dose-escalation trial published by Jastreboff et al. in 2023 in the New England Journal of Medicine, nausea, vomiting, decreased appetite, and headache were among the most commonly reported adverse events, particularly in early weeks of treatment. Nausea triggered by high-sugar or high-fat foods is a pattern also documented anecdotally and clinically across the GLP-1 class, including with semaglutide and tirzepatide. The gut slows gastric emptying, and rich foods sit longer than they used to. Eating sugary food and feeling queasy is not surprising. Her headaches resolving by week 3 also tracks. Early headaches are common during caloric restriction and hormonal adjustment and tend to improve as the body adapts.

What did they get wrong (or right)?

The science she describes? Mostly right. The framing around confidence, what she calls a "God complex," is harder to evaluate and worth being careful about.

There is no peer-reviewed evidence that retatrutide or GLP-1 class drugs cause elevated self-confidence as a pharmacological effect. There is emerging and preliminary observational data suggesting GLP-1 receptor agonists may influence mood and anxiety in some users, but that literature is early and inconsistent. A 2023 review in Frontiers in Endocrinology (Wharton et al.) noted mood effects as an area requiring further study, not a documented outcome. The confidence she describes may be real, but attributing it directly to retatrutide as a drug effect is a stretch. Weight loss and reduced hunger can absolutely improve how someone feels about themselves. That is a psychological response to physical change, not a pharmacological mechanism.

She does not overclaim on efficacy. She does not say she lost a specific amount of weight. She does not recommend doses. Credit where it is due.

What should you actually know?

Retatrutide is not approved by the FDA. It is not legally available through licensed U.S. pharmacies as a finished drug product. It is in Phase 3 trials as of 2024. Anyone using it outside a clinical trial is obtaining it from compounded or gray-market sources, and those products are not subject to the same manufacturing or purity standards as investigational drug supplies used in trials.

The side effect profile from the Jastreboff 2023 trial included nausea in roughly 45 to 50 percent of participants at higher doses, and the trial was conducted with careful dose escalation and medical supervision. Appetite suppression this significant, especially with no mention of protein intake or muscle preservation strategies, is a genuine concern. Loss of lean mass alongside fat mass is documented across the GLP-1 class. A 2023 study in Nature Medicine (Wilding et al., semaglutide) showed that without resistance training, a meaningful portion of weight lost can come from muscle. That risk is not retatrutide-specific, but it applies here.

If you are considering this compound based on videos like this one, that is your choice to make as an adult. But make it with full information, not just week-3 vibes.

The bottom line

The physiological side effects @chelseypeptides describes are consistent with the clinical trial data on retatrutide. Her report is more credible than a lot of what circulates in peptide content. The confidence boost is real to her but is not a documented pharmacological effect. The bigger picture concern is that retatrutide is an unapproved compound, and 20,000 viewers seeing a positive week-3 update without context about regulatory status, sourcing risks, or lean mass concerns is not a complete picture.